| First Author | Gan CL | Year | 2021 |
| Journal | Int J Biol Sci | Volume | 17 |
| Issue | 9 | Pages | 2356-2366 |
| PubMed ID | 34239362 | Mgi Jnum | J:308989 |
| Mgi Id | MGI:6753591 | Doi | 10.7150/ijbs.59922 |
| Citation | Gan CL, et al. (2021) Inhibition of Death-associated Protein Kinase 1 protects against Epileptic Seizures in mice. Int J Biol Sci 17(9):2356-2366 |
| abstractText | Epilepsy is a chronic encephalopathy and one of the most common neurological disorders. Death-associated protein kinase 1 (DAPK1) expression has been shown to be upregulated in the brains of human epilepsy patients compared with those of normal subjects. However, little is known about the impact of DAPK1 on epileptic seizure conditions. In this study, we aim to clarify whether and how DAPK1 is regulated in epilepsy and whether targeting DAPK1 expression or activity has a protective effect against epilepsy using seizure animal models. Here, we found that cortical and hippocampal DAPK1 activity but not DAPK1 expression was increased immediately after convulsive pentylenetetrazol (PTZ) exposure in mice. However, DAPK1 overexpression was found after chronic low-dose PTZ insults during the kindling paradigm. The suppression of DAPK1 expression by genetic knockout significantly reduced PTZ-induced seizure phenotypes and the development of kindled seizures. Moreover, pharmacological inhibition of DAPK1 activity exerted rapid antiepileptic effects in both acute and chronic epilepsy mouse models. Mechanistically, PTZ stimulated the phosphorylation of NR2B through DAPK1 activation. Combined together, these results suggest that DAPK1 regulation is a novel mechanism for the control of both acute and chronic epilepsy and provide new therapeutic strategies for the treatment of human epilepsy. |
